A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis

Catherine M. Ludwig; Jeffrey M. Krase; Kyla N. Price; Peter A. Lio; Vivian Y. Shi

doi:10.1080/09546634.2019.1682498

A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis

Catherine M. Ludwig, Jeffrey M. Krase, Kyla N. Price, Peter A. Lio, Vivian Y. Shi^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	503-506
Number of pages	4
Journal	Journal of Dermatological Treatment
Volume	32
Issue number	5
DOIs	https://doi.org/10.1080/09546634.2019.1682498
State	Published - 2021

ASJC Scopus subject areas

Dermatology

Access to Document

10.1080/09546634.2019.1682498

Cite this

@article{af78b08e39fc44c0889186b425b58d90,

title = "A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis",

author = "Ludwig, {Catherine M.} and Krase, {Jeffrey M.} and Price, {Kyla N.} and Lio, {Peter A.} and Shi, {Vivian Y.}",

note = "Funding Information: Vivian Shi is a stock shareholder of Dermveda, has served as an advisor for Sanofi Genzyme/Regeneron, AbbVie, Novartis, Sun Pharma, Pfizer, Menlo Therapeutics, Burt{\textquoteright}s Bees, GpSkin, the National Eczema Association and Global Parents for Eczema Research, is an investigator for AbbVie, Regeneron, Novartis, and Leo Pharma, and has received research funding from the Foundation for Atopic Dermatitis and Skin Actives Scientific. There were no incentives or transactions, financial or otherwise, relevant to this manuscript. Peter Lio has served as an investigator, speaker, advisory board member, and consultant for Sanofi Genzyme/Regeneron. There were no incentives or transactions, financial or otherwise, relevant to this manuscript. Catherine Ludwig, Kyla Price, and Jeffrey Krase have no potential conflicts of interest to declare. ",

year = "2021",

doi = "10.1080/09546634.2019.1682498",

language = "English (US)",

volume = "32",

pages = "503--506",

journal = "Journal of Dermatological Treatment",

issn = "0954-6634",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis

AU - Ludwig, Catherine M.

AU - Krase, Jeffrey M.

AU - Price, Kyla N.

AU - Lio, Peter A.

AU - Shi, Vivian Y.

N1 - Funding Information: Vivian Shi is a stock shareholder of Dermveda, has served as an advisor for Sanofi Genzyme/Regeneron, AbbVie, Novartis, Sun Pharma, Pfizer, Menlo Therapeutics, Burt’s Bees, GpSkin, the National Eczema Association and Global Parents for Eczema Research, is an investigator for AbbVie, Regeneron, Novartis, and Leo Pharma, and has received research funding from the Foundation for Atopic Dermatitis and Skin Actives Scientific. There were no incentives or transactions, financial or otherwise, relevant to this manuscript. Peter Lio has served as an investigator, speaker, advisory board member, and consultant for Sanofi Genzyme/Regeneron. There were no incentives or transactions, financial or otherwise, relevant to this manuscript. Catherine Ludwig, Kyla Price, and Jeffrey Krase have no potential conflicts of interest to declare.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85075486904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075486904&partnerID=8YFLogxK

U2 - 10.1080/09546634.2019.1682498

DO - 10.1080/09546634.2019.1682498

M3 - Letter

C2 - 31619094

AN - SCOPUS:85075486904

VL - 32

SP - 503

EP - 506

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 5

ER -

A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this